In the Lab

Health tech Brittany Trang

STAT Plus: For decades, they’ve set the record straight in biology. Next up: science’s reproducibility crisis

In the Lab Angus Chen

STAT Plus: Cancer cells can ‘barf’ proteins onto their cell surface. That may create new targets for immunotherapies

Exclusive Megan Molteni

STAT Plus: A new mystery emerges about Epstein’s involvement in Harvard genetics study

Biotech Jason Mast

STAT Plus: Prime Medicine to seek approval for gene-editing treatment after two-patient trial

Health Associated Press

Henrietta Lacks’ estate settles with Novartis over the ‘stolen cells’ that advanced science

Biotech Jason Mast

STAT Plus: Rare disease advocates fume over FDA’s mixed signals

Exclusive Megan Molteni

STAT Plus: Jeffrey Epstein’s tissue samples ignited a furor in the Harvard lab of George Church

Health Angus Chen

STAT Plus: Nature Medicine to investigate study that found cancer treatment is better in morning

In the Lab Anil Oza

With federal research funding uncertain, states debate new science initiatives

Politics Chelsea Cirruzzo and Anil Oza

STAT Plus: NIH Director Bhattacharya to lead CDC after O’Neill’s exit

In the Lab Jonathan Wosen

Students, faculty mystified as NSF turns back applications for prestigious fellowship program

In the Lab Jonathan Wosen

STAT Plus: Novartis’ biomedical research head on AI, pruning the pipeline, and a potential blockbuster

Biotech Jason Mast

STAT Plus: ‘Moonshot’ agency ARPA-H lays off staff meant to commercialize breakthroughs

In the Lab Jonathan Wosen

Junior scientists face a quandary when starting their own labs: How far to stray from the hive

In the Lab Jonathan Wosen

STAT Plus: Federal judge dismisses lawsuit against academic publishers over unpaid peer review

In the Lab Jonathan Wosen

Tenuous biomedical funding has put first-year Ph.D. students in a bind

Health tech Megan Molteni

STAT Plus: DeepMind releases AlphaGenome source code, aiming to improve its AI predictions of gene regulation

Biotech Jason Mast

STAT Plus: FDA’s new ‘plausible mechanism pathway’ for personalized gene editing raises concerns

Politics Megan Molteni

STAT Plus: Unfilled vacancies have depleted NIH advisory councils, key players in grant approvals

In the Lab Angus Chen

STAT Plus: Anthony Letai says NCI is more stable than perceived and is heading for a big year

In the Lab Andrew Joseph

STAT Plus: Novo Nordisk Foundation gives $850M to nonprofit to help commercialize research in Europe 

In the Lab Jonathan Wosen

Enrollment in biomedical degree programs rose last fall despite funding turmoil, new data show

Health Lev Facher

Trump administration reverses course on $1.9 billion in cuts to addiction and mental health grants

Biotech Jason Mast and Allison DeAngelis

STAT Plus: Key scientist from Baby KJ team launches startup to scale personalized CRISPR medicines

Health tech O. Rose Broderick

STAT Plus: What does Neuralink want — to help people with paralysis, or prepare for a war with AI?

In the Lab Angus Chen

Genetic variant appears to protect some people against certain blood cancers

Special Report Eric Boodman

NIH study was a beacon for the topical steroid withdrawal community. Then, amid federal upheaval, the research stalled

Health Lev Facher

Trump’s marijuana reclassification could boost research, broaden access

In the Lab Anil Oza and Jonathan Wosen

STAT Plus: NIH funding rates for early-career researchers plunged in 2025, new data show